|
1
|
Midorikawa Y, Ishikawa S, Iwanari H,
Imamura T, Sakamoto H, Miyazono K, Kodama T, Makuuchi M and
Aburatani H: Glypican-3, overexpressed in hepatocellular carcinoma,
modulates FGF2 and BMP-7 signaling. Int J Cancer. 103:455–465.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Filmus J and Selleck SB: Glypicans:
Proteoglycans with a surprise. J Clin Invest. 108:497–501. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nakatsura T, Yoshitake Y, Senju S, Monji
M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H,
et al: Glypican-3, overexpressed specifically in human
hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys
Res Commun. 306:16–25. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang XY, Degos F, Dubois S, Tessiore S,
Allegretta M, Guttmann RD, Jothy S, Belghiti J, Bedossa P and
Paradis V: Glypican-3 expression in hepatocellular tumors:
Diagnostic value for preneoplastic lesions and hepatocellular
carcinomas. Hum Pathol. 37:1435–1441. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Montalbano M, Rastellini C, Wang X,
Corsello T, Eltorky MA, Vento R and Cicalese L: Transformation of
primary human hepatocytes in hepatocellular carcinoma. Int J Oncol.
48:1205–1217. 2016.PubMed/NCBI
|
|
6
|
Montalbano M, Curcurù G, Shirafkan A,
Vento R, Rastellini C and Cicalese L: Modeling of hepatocytes
proliferation isolated from proximal and distal zones from human
hepatocellular carcinoma lesion. PLoS One. 11:e01536132016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sung YK, Hwang SY, Park MK, Farooq M, Han
IS, Bae HI, Kim JC and Kim M: Glypican-3 is overexpressed in human
hepatocellular carcinoma. Cancer Sci. 94:259–262. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stigliano I, Puricelli L, Filmus J,
Sogayar MC, Bal de Kier Joffé E and Peters MG: Glypican-3 regulates
migration, adhesion and actin cytoskeleton organization in mammary
tumor cells through Wnt signaling modulation. Breast Cancer Res
Treat. 114:251–262. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pellegrini M, Pilia G, Pantano S, Lucchini
F, Uda M, Fumi M, Cao A, Schlessinger D and Forabosco A: Gpc3
expression correlates with the phenotype of the
Simpson-Golabi-Behmel syndrome. Dev Dyn. 213:431–439. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim H, Xu GL, Borczuk AC, Busch S, Filmus
J, Capurro M, Brody JS, Lange J, D'Armiento JM, Rothman PB, et al:
The heparan sulfate proteoglycan GPC3 is a potential lung tumor
suppressor. Am J Respir Cell Mol Biol. 29:694–701. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ho M and Kim H: Glypican-3: A new target
for cancer immunotherapy. Eur J Cancer. 47:333–338. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lai JP, Sandhu DS, Yu C, Han T, Moser CD,
Jackson KK, Guerrero RB, Aderca I, Isomoto H, Garrity-Park MM, et
al: Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth
factor signaling, and decreases survival in hepatocellular
carcinoma. Hepatology. 47:1211–1222. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bhave VS, Mars W, Donthamsetty S, Zhang X,
Tan L, Luo J, Bowen WC and Michalopoulos GK: Regulation of liver
growth by glypican 3, CD81, hedgehog, and Hhex. Am J Pathol.
183:153–159. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Michalopoulos GK: Regenerative responses
to liver injury. Eur J Med Res. 19 Suppl 1:S12014.doi:
10.1186/2047-783X-19-S1-S1. View Article : Google Scholar :
|
|
15
|
Iglesias BV, Centeno G, Pascuccelli H,
Ward F, Peters MG, Filmus J, Puricelli L and de Kier Joffé EB:
Expression pattern of glypican-3 (GPC3) during human embryonic and
fetal development. Histol Histopathol. 23:1333–1340.
2008.PubMed/NCBI
|
|
16
|
Golabi M, Leung A and Lopez C:
Simpson-Golabi-Behmel syndrome type 1.
GeneReviews®[Internet]. Pagon RA, Adam MP, Ardinger HH,
et al: University of Washington; Seattle, Seattle, WA: pp.
1993–2016. 2006 June 23–2011
|
|
17
|
Khan S, Blackburn M, Mao DL, Huber R,
Schlessinger D and Fant M: Glypican-3 (GPC3) expression in human
placenta: Localization to the differentiated syncytiotrophoblast.
Histol Histopathol. 16:71–78. 2001.PubMed/NCBI
|
|
18
|
DeBaun MR, Ess J and Saunders S: Simpson
Golabi Behmel syndrome: Progress toward understanding the molecular
basis for overgrowth, malformation, and cancer predisposition. Mol
Genet Metab. 72:279–286. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Baumhoer D, Tornillo L, Stadlmann S,
Roncalli M, Diamantis EK and Terracciano LM: Glypican 3 expression
in human nonneoplastic, preneoplastic, and neoplastic tissues: A
tissue microarray analysis of 4,387 tissue samples. Am J Clin
Pathol. 129:899–906. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao H, Li K, Tu H, Pan X, Jiang H, Shi B,
Kong J, Wang H, Yang S, Gu J, et al: Development of T cells
redirected to glypican-3 for the treatment of hepatocellular
carcinoma. Clin Cancer Res. 20:6418–6428. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Feng M and Ho M: Glypican-3 antibodies: A
new therapeutic target for liver cancer. FEBS Lett. 588:377–382.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hsu HC, Cheng W and Lai PL: Cloning and
expression of a developmentally regulated transcript MXR7 in
hepatocellular carcinoma: Biological significance and
temporospatial distribution. Cancer Res. 57:5179–5184.
1997.PubMed/NCBI
|
|
23
|
Zynger DL, Dimov ND, Luan C, Teh BT and
Yang XJ: Glypican 3: A novel marker in testicular germ cell tumors.
Am J Surg Pathol. 30:1570–1575. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Castillo L, Huvelle MAL, Fujita A, Lobba
ARM, Tascon R and Peters MG: Expression of glypican-3 (GPC3) in
malignant and non-malignant human breast tissues. Open Cancer J.
8:12–23. 2015.https://benthamopen.com/contents/pdf/TOCJ/TOCJ-8-12.pdf
View Article : Google Scholar
|
|
25
|
Xiang YY, Ladeda V and Filmus J:
Glypican-3 expression is silenced in human breast cancer. Oncogene.
20:7408–7412. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Man XB, Tang L, Zhang BH, Li SJ, Qiu XH,
Wu MC and Wang HY: Upregulation of Glypican-3 expression in
hepatocellular carcinoma but downregulation in cholangiocarcinoma
indicates its differential diagnosis value in primary liver
cancers. Liver Int. 25:962–966. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lin H, Huber R, Schlessinger D and Morin
PJ: Frequent silencing of the GPC3 gene in ovarian cancer cell
lines. Cancer Res. 59:807–810. 1999.PubMed/NCBI
|
|
28
|
Nakatsura T, Kageshita T, Ito S, Wakamatsu
K, Monji M, Ikuta Y, Senju S, Ono T and Nishimura Y: Identification
of glypican-3 as a novel tumor marker for melanoma. Clin Cancer
Res. 10:6612–6621. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Luo JH, Ren B, Keryanov S, Tseng GC, Rao
UN, Monga SP, Strom S, Demetris AJ, Nalesnik M, Yu YP, et al:
Transcriptomic and genomic analysis of human hepatocellular
carcinomas and hepatoblastomas. Hepatology. 44:1012–1024. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu B, Paranjpe S, Bowen WC, Bell AW, Luo
JH, Yu YP, Mars WM and Michalopoulos GK: Investigation of the role
of glypican 3 in liver regeneration and hepatocyte proliferation.
Am J Pathol. 175:717–724. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ahmed SS, Ola A, Ahmed E and Mohammed A:
Seroprevalence of Glypican-3 (GPC-3) in patients with pancreatic,
gastric and esophageal cancers. NY Sci J. 4:45–50. 2011.http://www.sciencepub.net/newyork/ny0407/08_6074ny0407_45_50.pdf
|
|
32
|
Yamanaka K, Ito Y, Okuyama N, Noda K,
Matsumoto H, Yoshida H, Miyauchi A, Capurro M, Filmus J and Miyoshi
E: Immunohistochemical study of glypican 3 in thyroid cancer.
Oncology. 73:389–394. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gailey MP and Bellizzi AM:
Immunohistochemistry for the novel markers glypican 3, PAX8, and
p40 (∆Np63) in squamous cell and urothelial carcinoma. Am J Clin
Pathol. 140:872–880. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ushiku T, Uozaki H, Shinozaki A, Ota S,
Matsuzaka K, Nomura S, Kaminishi M, Aburatani H, Kodama T and
Fukayama M: Glypican 3-expressing gastric carcinoma: Distinct
subgroup unifying hepatoid, clear-cell, and
alpha-fetoprotein-producing gastric carcinomas. Cancer Sci.
100:626–632. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Aydin O, Yildiz L, Baris S, Dundar C and
Karagoz F: Expression of Glypican 3 in low and high grade
urothelial carcinomas. Diagn Pathol. 10:342015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chan ES, Pawel BR, Corao DA, Venneti S,
Russo P, Santi M and Sullivan LM: Immunohistochemical expression of
glypican-3 in pediatric tumors: An analysis of 414 cases. Pediatr
Dev Pathol. 16:272–277. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gonzalez AD, Kaya M, Shi W, Song H, Testa
JR, Penn LZ and Filmus J: OCI-5/GPC3, a glypican encoded by a gene
that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome,
induces apoptosis in a cell line-specific manner. J Cell Biol.
141:1407–1414. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Murthy SS, Shen T, De Rienzo A, Lee WC,
Ferriola PC, Jhanwar SC, Mossman BT, Filmus J and Testa JR:
Expression of GPC3, an X-linked recessive overgrowth gene, is
silenced in malignant mesothelioma. Oncogene. 19:410–416. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yu X, Li Y, Chen SW, Shi Y and Xu F:
Differential expression of glypican-3 (GPC3) in lung squamous cell
carcinoma and lung adenocarcinoma and its clinical significance.
Genet Mol Res. 14:10185–10192. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mounajjed T, Zhang L and Wu TT: Glypican-3
expression in gastrointestinal and pancreatic epithelial neoplasms.
Hum Pathol. 44:542–550. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Valsechi MC, Oliveira AB, Conceição AL,
Stuqui B, Candido NM, Provazzi PJ, de A, raújo LF, Silva WA Jr,
Calmon Mde F and Rahal P: GPC3 reduces cell proliferation in renal
carcinoma cell lines. BMC Cancer. 14:6312014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang L, Liu H, Sun L, Li N, Ding H and
Zheng J: Glypican-3 as a potential differential diagnosis marker
for hepatocellular carcinoma: A tissue microarray-based study. Acta
Histochem. 114:547–552. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Huang TS, Shyu YC, Turner R, Chen HY and
Chen PJ: Diagnostic performance of alpha-fetoprotein, lens
culinaris agglutinin-reactive alpha-fetoprotein, des-gamma
carboxyprothrombin, and glypican-3 for the detection of
hepatocellular carcinoma: A systematic review and meta-analysis
protocol. Syst Rev. 2:372013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang Y, Yang H, Xu H, Lu X, Sang X, Zhong
S, Huang J and Mao Y: Golgi protein 73, not Glypican-3, may be a
tumor marker complementary to α-Fetoprotein for hepatocellular
carcinoma diagnosis. J Gastroenterol Hepatol. 29:597–602. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Feng J, Zhu R, Chang C, Yu L, Cao F, Zhu
G, Chen F, Xia H, Lv F, Zhang S, et al: CK19 and Glypican 3
expression profiling in the prognostic indication for patients with
HCC after surgical resection. PLoS One. 11:e01515012016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu B, Bell AW, Paranjpe S, Bowen WC,
Khillan JS, Luo JH, Mars WM and Michalopoulos GK: Suppression of
liver regeneration and hepatocyte proliferation in
hepatocyte-targeted glypican 3 transgenic mice. Hepatology.
52:1060–1067. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhu AX, Gold PJ, El-Khoueiry AB, Abrams
TA, Morikawa H, Ohishi N, Ohtomo T and Philip PA: First-in-man
phase I study of GC33, a novel recombinant humanized antibody
against glypican-3, in patients with advanced hepatocellular
carcinoma. Clin Cancer Res. 19:920–928. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Huang N, Lin J, Ruan J, Su N, Qing R, Liu
F, He B, Lv C, Zheng D and Luo R: MiR-219-5p inhibits
hepatocellular carcinoma cell proliferation by targeting
glypican-3. FEBS Lett. 586:884–891. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Park JO, Stephen Z, Sun C, Veiseh O,
Kievit FM, Fang C, Leung M, Mok H and Zhang M: Glypican-3 targeting
of liver cancer cells using multifunctional nanoparticles. Mol
Imaging. 10:69–77. 2011.PubMed/NCBI
|
|
50
|
Zhu D, Qin Y, Wang J, Zhang L, Zou S, Zhu
X and Zhu L: Novel glypican-3-binding peptide for in vivo
hepatocellular carcinoma fluorescent imaging. Bioconjug Chem.
27:831–839. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kunej T, Skok DJ, Horvat S, Dovc P and
Jiang Z: The glypican 3-hosted murine mir717 gene: Sequence
conservation, seed region polymorphisms and putative targets. Int J
Biol Sci. 6:769–772. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kew MC: Obesity as a cause of
hepatocellular carcinoma. Ann Hepatol. 14:299–303. 2015.PubMed/NCBI
|
|
53
|
Filmus J and Capurro M: The role of
glypican-3 in the regulation of body size and cancer. Cell Cycle.
7:2787–2790. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Filmus J and Capurro M: Glypican-3: A
marker and a therapeutic target in hepatocellular carcinoma. FEBS
J. 280:2471–2476. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Tsuda M, Kamimura K, Nakato H, Archer M,
Staatz W, Fox B, Humphrey M, Olson S, Futch T, Kaluza V, et al: The
cell-surface proteoglycan Dally regulates Wingless signalling in
Drosophila. Nature. 400:276–280. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
56
|
Song HH, Shi W, Xiang YY and Filmus J: The
loss of glypican-3 induces alterations in Wnt signaling. J Biol
Chem. 280:2116–2125. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Capurro MI, Xiang YY, Lobe C and Filmus J:
Glypican-3 promotes the growth of hepatocellular carcinoma by
stimulating canonical Wnt signaling. Cancer Res. 65:6245–6254.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Lee YL, Ahn B-C, Lee Y, Lee S-W, Cho J-Y
and Lee J: Targeting of hepatocellular carcinoma with
glypican-3-targeting peptide ligand. J Pept Sci. 17:763–769. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Yorita K, Takahashi N, Takai H, Kato A,
Suzuki M, Ishiguro T, Ohtomo T, Nagaike K, Kondo K, Chijiiwa K, et
al: Prognostic significance of circumferential cell surface
immunoreactivity of glypican-3 in hepatocellular carcinoma. Liver
Int. 31:120–131. 2011. View Article : Google Scholar : PubMed/NCBI
|
